Divi's Labs approves FY26 results, recommends ₹30 dividend; AGM on Aug 10
Divi's Laboratories approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company recommended a final dividend of ₹30 per share for FY26. The 36th AGM is scheduled for August 10, 2026, with a record date of July 24, 2026. Standalone PAT was ₹756 crore for Q4FY26, and consolidated PAT was ₹751 crore.
The declaration of financial results and a significant dividend recommendation are material events that directly impact investors and the company's valuation.
The announcement includes the approval of financial results and a strong dividend recommendation, which are positive indicators for shareholders.
Divi's Laboratories Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board approved the audited financial results for the quarter and year ended March 31, 2026, both on a standalone and consolidated basis.
For the financial year 2025-26, the company recommended a final dividend of ₹30 per equity share (1,500%) subject to shareholder approval at the upcoming 36th Annual General Meeting (AGM). The AGM is scheduled for August 10, 2026, and the record date for dividend payment is July 24, 2026. The dividend will be paid within specified timelines post-AGM.
The company also reported its financial performance. For the quarter ended March 31, 2026, standalone profit after tax was ₹756 crore, compared to ₹598 crore in the previous year. Consolidated profit after tax for the same period stood at ₹751 crore, up from ₹583 crore in the prior year. The full financial year saw a standalone profit after tax of ₹2,607 crore and a consolidated profit after tax of ₹2,568 crore.
The financial statements were audited by Price Waterhouse Chartered Accountants LLP, who issued an unmodified report. The Board meeting commenced at 10:15 Hrs and concluded at 11:50 Hrs.
What to do with a filing like this
Divi's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Divi's Laboratories Limited. Read the original for the full detail.